Publications
89
Citations
5,494
Est. group size
—
Recurring co-author estimate
Active years
38
Publishing since 1988
Michael H. Cardone's research focuses on how cancer cells evade programmed cell death (apoptosis), particularly through proteins like Mcl-1, and how this affects the response to cancer therapies in cancers such as breast, lung, and leukemia. A major focus is developing biomarker tools (such as BH3 profiling and protein interaction assays) to predict which patients will respond to apoptosis-inducing drugs, including BH3-mimetic drugs used in leukemia treatment. This work bridges basic cell biology with practical tools for personalizing cancer treatment.
Publication output was minimal or absent in several years of the past decade, then spiked sharply in 2023 with a large cluster of related supplementary materials, followed by a return to lower annual counts in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Development of a Novel Biomarker Platform for Profiling Key Protein–Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs
Cancers · 2025
- Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications
Breast Cancer Research · 2024
- Abstract A024: Assessing Mitondiral Priming in Leukemia Using BH3 Complex Specific Antibodies (PRIMABS): Prediciting Patient Response to Apoptosis Inducing Drugs
Molecular Cancer Therapeutics · 2024
- Supplementary Figure 7 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Supplementary Methods and Figure Legends from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Data from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Data from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
2023
- Supplementary Figure 4 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Supplementary Figure 5 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Supplementary Figure 3 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Supplementary Figure 6 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Supplementary Methods and Figure Legends from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Supplementary Figure 1 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Supplementary Figure 7 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Supplementary Figure 2 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
2023
- Journal of Clinical Oncology×3
- Breast Cancer Research×2
- Cancer Research×2
- Oncotarget×1
- Haematologica×1
- Yumin Dai
Medicine · Purdue University West Lafayette
- Aravind Kalathil
Medicine · The Ohio State University
- Carlo M. Croce
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Anita C. Bellail
Biochemistry, Genetics and Molecular Biology · Indiana University
- Chunhai Hao
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile